Detalhe da pesquisa
1.
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
Ann Oncol
; 32(3): 395-403, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33276076
2.
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.
Ann Oncol
; 30(12): 1978-1984, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31553438
3.
A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
Ann Oncol
; 28(9): 2241-2247, 2017 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28911085
4.
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Br J Cancer
; 109(11): 2803-9, 2013 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-24169346
5.
Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.
Ann Oncol
; 24(5): 1326-31, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23277482
6.
An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting.
Ann Oncol
; 23(11): 2914-2919, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22776705
7.
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
ESMO Open
; 7(4): 100527, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35843080
8.
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
Eur J Cancer
; 107: 124-132, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30562710
9.
Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy.
Int J Radiat Oncol Biol Phys
; 51(2): 291-5, 2001 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11567801
10.
Clinical significance of the increased peak levels of exhaled nitric oxide in patients with bronchial asthma.
Intern Med
; 35(4): 270-5, 1996 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-8739780
11.
[Inhibitory effect of low molecular weight heparin on the bronchoconstriction in ovalbumin-sensitized guinea pigs after antigen exposure].
Arerugi
; 44(11): 1282-9, 1995 Nov.
Artigo
em Japonês
| MEDLINE | ID: mdl-8857107
12.
[Psychiatric studies of chemotherapy and chemotherapy-induced nausea and vomiting of patients with lung or thymic cancer].
Gan To Kagaku Ryoho
; 25(3): 403-8, 1998 Feb.
Artigo
em Japonês
| MEDLINE | ID: mdl-9492835
13.
[Refractory non-small-cell lung cancer responding to combination chemotherapy with docetaxel, gemcitabine and cisplatin].
Gan To Kagaku Ryoho
; 28(1): 105-9, 2001 Jan.
Artigo
em Japonês
| MEDLINE | ID: mdl-11201378
14.
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.
Br J Cancer
; 96(8): 1191-6, 2007 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-17387341